By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boehringer Ingelheim GmbH 

Binger Str. 173

Ingelheim    D-55126  Germany
Phone: 49-6132-77-0 Fax: 49-6132-72-0



Company News
Boehringer Ingelheim GmbH Release: FDA Medicare Study In 134,000 Atrial Fibrillation Patients Confirms Positive Safety Profile And Effectiveness Of Pradaxa® In General Practice 11/3/2014 10:59:51 AM
Boehringer Ingelheim GmbH Withheld Evidence On Blockbuster Blood Thinner 7/24/2014 7:17:36 AM
Boehringer Ingelheim GmbH Release: Type 2 Diabetes: Physicians Worldwide Agree Early Conversations Are Crucial In The Management Of Condition 6/16/2014 10:42:02 AM
Boehringer Ingelheim GmbH Release: New Study To Investigate Dabigatran Etexilate For Prevention Of Recurrent Stroke In High-Risk Patients 5/7/2014 8:25:42 AM
Boehringer Ingelheim GmbH Release: Better Outcome in Case of Major Bleed for Patients Taking the Anticoagulant Pradaxa® Compared to Warfarin 10/7/2013 10:01:24 AM
Boehringer Ingelheim GmbH Release: Data Presented at EASD Support Safety Profile of Trajenta® (Linagliptin) In Broad Range of Adults With Type 2 Diabetes 9/24/2013 6:38:50 AM
Boehringer Ingelheim GmbH's Respimat Inhaler Meets Safety Goal in Study 9/3/2013 8:08:54 AM
Swedish Orphan Biovitrum Gets FDA Approval to Manufacture Substance for Kineret® With Partner Boehringer Ingelheim Corporation 6/11/2013 9:48:34 AM
Boehringer Ingelheim GmbH and Eli Lilly and Company (LLY) Alliance to Feature 34 Presentations in Type 1 and Type 2 Diabetes at the 73rd American Diabetes Association Scientific Sessions® 6/11/2013 6:53:52 AM
Boehringer Ingelheim GmbH Release: FDA and FDA Reaffirm Important Health Benefits and Safety of Pradaxa® (dabigatran etexilate) for Patients With Atrial Fibrillation 11/5/2012 9:55:43 AM